Related Experiment Video
Updated: Nov 28, 2025
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
Elisa Rumi1,2, Chiara Trotti1, Daniele Vanni1
1Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
Abstract:
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is the most aggressive subtype from a clinical standpoint, posing a great challenge to clinicians. Whilst the biological consequences of the three MPN driver gene mutations (JAK2, CALR, and MPL) have been well described, recent data has shed light on the complex and dynamic structure of PMF, that involves competing disease subclones, sequentially acquired genomic events, mostly in genes that are recurrently mutated in several myeloid neoplasms and in clonal hematopoiesis, and biological interactions between clonal hematopoietic stem cells and abnormal bone marrow niches. These observations may contribute to explain the wide heterogeneity in patients' clinical presentation and prognosis, and support the recent effort to include molecular information in prognostic scoring systems used for therapeutic decision-making, leading to promising clinical translation. In this review, we aim to address the topic of PMF molecular genetics, focusing on four questions: (1) what is the role of mutations on disease pathogenesis? (2) what is their impact on patients' clinical phenotype? (3) how do we integrate gene mutations in the risk stratification process? (4) how do we take advantage of molecular genetics when it comes to treatment decisions?
Insights
Primary myelofibrosis (PMF) is an aggressive blood cancer. Understanding its complex molecular genetics, including driver mutations and clonal evolution, improves risk assessment and treatment decisions for patients.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Primary myelofibrosis (PMF) is the most aggressive Philadelphia chromosome-negative myeloproliferative neoplasm.
- Driver mutations (JAK2, CALR, MPL) are known, but PMF complexity involves subclones, genomic events, and niche interactions.
- Patient heterogeneity in presentation and prognosis presents a clinical challenge.
Purpose of the Study:
- To review the molecular genetics of PMF.
- To explore the role of mutations in pathogenesis and clinical phenotype.
- To discuss integrating molecular data into risk stratification and treatment decisions.
Main Methods:
- Literature review of PMF molecular genetics.
- Analysis of current understanding of driver mutations and clonal evolution.
- Discussion of prognostic scoring systems and therapeutic strategies.
Main Results:
- PMF pathogenesis is complex, involving driver mutations, acquired genomic events, and bone marrow microenvironment interactions.
- Molecular findings explain patient heterogeneity and support their inclusion in prognostic models.
- Gene mutations are increasingly vital for risk stratification and guiding treatment.
Conclusions:
- Molecular genetics is crucial for understanding PMF pathogenesis and heterogeneity.
- Integrating molecular data into clinical practice enhances risk assessment and personalized treatment strategies.
- Further research into PMF molecular landscape will refine therapeutic approaches.
